1. Describe barriers to using olanzapine for CINV prophylaxis.

2. Review clinical trials and guidelines of olanzapine for CINV prophylaxis.

3. Identify prescribing patterns of olanzapine for CINV prophylaxis before and after educational efforts.

Session date: 
06/13/2019 - 8:00am to 9:00am CDT
Evanston, IL 60201
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Christopher W. Kapolas, Pharm.D.